2192 — Medlive Technology Co Balance Sheet
0.000.00%
- HK$7.41bn
- HK$3.50bn
- CNY558.46m
- 86
- 39
- 32
- 53
Annual balance sheet for Medlive Technology Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 147 | 3,909 | 4,217 | 4,401 | 4,146 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 58.2 | 95.9 | 124 | 156 | 175 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 208 | 4,013 | 4,352 | 4,573 | 4,356 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 15.2 | 16.9 | 14.6 | 11.1 | 38 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 227 | 4,116 | 4,603 | 4,894 | 5,108 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 64.1 | 113 | 133 | 190 | 207 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 75.6 | 167 | 202 | 296 | 309 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 151 | 3,949 | 4,401 | 4,597 | 4,799 |
| Total Liabilities & Shareholders' Equity | 227 | 4,116 | 4,603 | 4,894 | 5,108 |
| Total Common Shares Outstanding |